Effects of bortezomib combined with ifosfamide, methylprednisolone and thalidomide for the treatment of multiple myeloma
10.3760/cma.j.issn.1009-9921.2011.02.006
- VernacularTitle:硼替佐米联合异环磷酰胺、甲泼尼龙、沙利度胺方案治疗多发性骨髓瘤
- Author:
Na AN
;
Xin LI
;
Yuping ZHONG
;
Ying HU
;
Jiajia ZHANG
;
Xiaohui LIU
;
Shilun CHEN
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Antineoplastic combined chemotherapy protocols;
Bortezomib;
Ifosfamide;
Methylprednisolone;
Thalidomide
- From:
Journal of Leukemia & Lymphoma
2011;20(2):79-81,85
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and toxicity of bortezomib in combination with ifosfamide, methylprednisolone, thalidomide (V-CMPT) for the treatment of multiple myeloma (MM). Methods Twenty-four patients with newly diagnosed or relapsed/refractory MM were treated with V-CMPT. This regimen was repeated every three weeks as one cycle, and each case received two cycles. We adopted the examination of bone marrow and M protein and other hematological markers to evaluate the condition of disease and the therapeutic response. Results Of the nine patients with newly diagnosed MM, three achieved a complete remission (CR), five of a partial response (PR), and 1 of a minor response (MR). Of the patients with relapsed/refractory MM, two achieved a CR, two had a near CR (nCR), three had a PR, six had a MR, and two were no chang (NC). There was no obvious difference in the two groups (P = 0.511, P = 1.000). The overall response rate (ORR) was 91.7 %, and the CR/nCR rate was 29.2 %. After two cycles, the levels of hemoglobin, the serum albumin and the serum β2-microglobulin were obviously improved. The main adverse events were transient, including gastrointestinal reaction, thrombocytopenia, neuropathy, which could be controlled during the interval of chemotherapy or by symptomatic treatment and had no influence on the chemotherapy.Conclusion V-CMPT regiman was effective against the newly diagnosed and relapsed/refractory MM and could improve the related hematological markers with high response rate and tolerable toxicities.
